NCT03901469: A trial that was reported late by Zenith Epigenetics
This trial has reported, although it was 7 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03901469 |
|---|---|
| Title | A Phase 2b Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breast Cancer |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 26, 2019 |
| Completion date | March 7, 2024 |
| Required reporting date | March 7, 2025, midnight |
| Actual reporting date | March 14, 2025 |
| Date last checked at ClinicalTrials.gov | March 30, 2026 |
| Days late | 7 |